The potential therapeutic role of IL-35 in pathophysiological processes in type 1 diabetes mellitus

[Display omitted] •T1DM has characteristics marked with a gradual immune-mediated deterioration of the β-cells producing insulin.•IL-35 has potential role as an effective autoimmune inhibitor and has potential therapeutic value in T1DM clinical trials.•Administration of IL-35, could block effector T...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cytokine (Philadelphia, Pa.) Pa.), 2024-10, Vol.182, p.156732, Article 156732
Hauptverfasser: Bakery, Heba H., Hussein, Heba A.A., Ahmed, Osama M., Abuelsaad, Abdelaziz S.A., Khalil, Rehab G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] •T1DM has characteristics marked with a gradual immune-mediated deterioration of the β-cells producing insulin.•IL-35 has potential role as an effective autoimmune inhibitor and has potential therapeutic value in T1DM clinical trials.•Administration of IL-35, could block effector Th1 and Th17 and has a positive feedback effect.•IL-35 boosting Treg, IL-35-producing iTreg35, and IL-35-producing iBreg35 expansion. A chronic autoimmune condition known as type 1 diabetes mellitus (T1DM) has characteristics marked by a gradual immune-mediated deterioration of the β-cells that produce insulin and causes overt hyperglycemia. it affects more than 1.2 million kids and teenagers (0–19 years old). In both, the initiation and elimination phases of T1DM, cytokine-mediated immunity is crucial in controlling inflammation. T regulatory (Treg) cells, a crucial anti-inflammatory CD4+ T cell subset, secretes interleukin-35 (IL-35). The IL-35 has immunomodulatory properties by inhibiting pro-inflammatory cells and cytokines, increasing the secretion of interleukin-10 (IL-10) as well as transforming Growth Factor- β (TGF-β), along with stimulating the Treg and B regulatory (Breg) cells. IL-35, it is a possible target for cutting-edge therapies for cancers, inflammatory, infectious, and autoimmune diseases, including TIDM. Unanswered questions surround IL-35’s function in T1DM. Increasing data suggests Treg cells play a crucial role in avoiding autoimmune T1DM. Throughout this review, we will explain the biological impacts of IL-35 and highlight the most recently progresses in the roles of IL-35 in treatment of T1DM; the knowledge gathered from these findings might lead to the development of new T1DM treatments. This review demonstrates the potential of IL-35 as an effective autoimmune diabetes inhibitor and points to its potential therapeutic value in T1DM clinical trials.
ISSN:1043-4666
1096-0023
1096-0023
DOI:10.1016/j.cyto.2024.156732